@article{8ccf64bb4d074e019574ee0a1d888a93,
title = "Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks",
abstract = " Objective: Antihistamines often have sedative side effects. This was the first study to measure regional cerebral glucose (energy) consumption and hemodynamic responses in young adults during cognitive tests after antihistamine administration. Methods: In this double-blind, placebo-controlled, three-way crossover study, 18 healthy young Japanese men received single doses of levocetirizine 5 mg and diphenhydramine 50 mg at intervals of at least six days. Subjective feeling, task performances, and brain activity were evaluated during three cognitive tests (word fluency, two-back, and Stroop). Regional cerebral glucose consumption changes were measured using positron emission tomography with [ 18 F]fluorodeoxyglucose. Regional hemodynamic responses were measured using near-infrared spectroscopy. Results: Energy consumption in prefrontal regions was significantly increased after antihistamine administration, especially diphenhydramine, whereas prefrontal hemodynamic responses, evaluated with oxygenated hemoglobin levels, were significantly lower with diphenhydramine treatment. Stroop test accuracy was significantly impaired by diphenhydramine, but not by levocetirizine. There was no significant difference in subjective sleepiness. Conclusions: Physiological “coupling” between metabolism and perfusion in the healthy human brain may not be maintained under pharmacological influence due to antihistamines. This uncoupling may be caused by a combination of increased energy demands in the prefrontal regions and suppression of vascular permeability in brain capillaries after antihistamine treatment. Further research is needed to validate this hypothesis.",
keywords = "antihistamines, diphenhydramine, FDG-PET, levocetirizine, NIRS, sedation",
author = "Asuka Kikuchi and Nasir, {Fairuz Binti Mohammadi} and Akie Inami and Attayeb Mohsen and Shoichi Watanuki and Masayasu Miyake and Kazuko Takeda and Daigo Koike and Takayasu Ito and Junpei Sasakawa and Rin Matsuda and Kotaro Hiraoka and Marcus Maurer and Kazuhiko Yanai and Hiroshi Watabe and Manabu Tashiro",
note = "Funding Information: M. Tashiro declares potential conflicts of interest regarding the present study because this study was supported by a collaboration research grant from GlaxoSmithKline (to M. Tashiro). K. Yanai, H. Watabe, and K. Hiraoka declare potential conflicts of interest as major collaborators in the present study. Funding Information: M. Tashiro, K. Yanai, H. Watabe, and K. Hiraoka have potential conflicts of interest regarding the present study. The present study was supported by a collaboration research grant from GlaxoSmithKline (to M. Tashiro). This study was also partly supported by Grants‐in‐Aid for Scientific Research (B; 17H04118) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to H. Watabe). We thank Mr. Yuma Arakawa for his support with PET scanning. We thank Ms. Senri Oyama and Mr. Takato Inomata for their support in NIRS data analysis. We thank Mrs. Chiyuki Onose for her contribution as a clinical research coordinator. We also thank Mr. Akihiro Ishikawa of Funding Information: M. Tashiro, K. Yanai, H. Watabe, and K. Hiraoka have potential conflicts of interest regarding the present study. The present study was supported by a collaboration research grant from GlaxoSmithKline (to M. Tashiro). This study was also partly supported by Grants-in-Aid for Scientific Research (B; 17H04118) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to H. Watabe). We thank Mr. Yuma Arakawa for his support with PET scanning. We thank Ms. Senri Oyama and Mr. Takato Inomata for their support in NIRS data analysis. We thank Mrs. Chiyuki Onose for her contribution as a clinical research coordinator. We also thank Mr. Akihiro Ishikawa of Shimadzu Corp., Kyoto, Japan, for technical support and encouragement. Publisher Copyright: {\textcopyright} 2018 The Authors Human Psychopharmacology: Clinical and Experimental Published by John Wiley & Sons Ltd.",
year = "2018",
month = mar,
doi = "10.1002/hup.2655",
language = "English",
volume = "33",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "2",
}